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Abstract 7 
Mitochondrial abnormalities have been identified as a central mechanism in multiple 8 
neurodegenerative diseases and therefore the mitochondria have been explored as a 9 
therapeutic target. This review will focus on the evidence for mitochondrial abnormalities 10 
in the two most common neurodegenerative diseases, Parkinson's disease and 11 
Alzheimer's disease. In addition, we discuss the main strategies which have been 12 
explored in these diseases to target the mitochondria for therapeutic purposes; focusing 13 
on mitochondrially targeted anti-oxidants, peptides, modulators of mitochondrial 14 
dynamics and phenotypic screening outcomes. 15 
Introduction to mitochondria 16 
The mitochondria are essential organelles to all eukaryotic cells. They are a highly 17 
dynamic double membrane-bound structure, containing their own circular, double 18 
stranded mitochondrial DNA (mtDNA), distinct from nuclear DNA [1]. Oxidative 19 
phosphorylation is the pathway via which mitochondria generate ATP, meeting most of 20 
the cells energy requirements. This is carried out by five protein complexes (complexes 21 
I-V). During oxidative phosphorylation, an electrochemical gradient is produced between 22 
the inner membrane and matrix of the mitochondria, which drives the synthesis of ATP 23 
[2,3]
. The mitochondria are also essential in other functions such as calcium buffering, 24 
steroid hormone synthesis, and apoptosis [1,4]. Mitochondrial functions have been 25 
reviewed elsewhere in detail, see Nunnari & Suomalainen (2012) [1]. The mitochondria 26 
decrease both in quality and functionality over the course of ageing [5], and 27 
mitochondrial dysfunction has been shown in age-related neurodegenerative disorders 28 
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VXFKDV3DUNLQVRQ¶VDQG$O]KHLPHU¶VGLVHDVH7KLVUHYLHZZLOOGLVFXVVWKHPLWRFKRQGULDO29 
alterations that have been seen in these diseases and review therapeutics targeting 30 
mitochondrial dysfunction.  31 
0LWRFKRQGULDODOWHUDWLRQVLQ3DUNLQVRQ¶VGLVHDVH 32 
3DUNLQVRQ¶VGLVHDVH3'LVDSURJUHVVLYHQHXURGHJHQHUDWLYHPRWRUGLVRUGHUZKLFK33 
affects approximately 1% of the over 60 population [6]. PD is characterised by the 34 
degeneration of dopaminergic neurons within the substantia nigra, leading to symptoms 35 
of bradykinesia, resting tremor, and muscle rigidity [7]. The disease can also present with 36 
non-motor symptoms, such as sleep dysfunction, cognitive impairment, and depression 37 
[7]
. The nigral neurons, the major cell type affected by PD, are highly susceptible to 38 
mitochondrial dysfunction due to high basal rates of oxidative phosphorylation leading to 39 
increased oxidative stress [8], and high densities of mitochondria in cultured neuron 40 
unmyelinated axons compared to other neuron types [9]. The initial link between 41 
mitochondrial dysfunction and PD was founded in the 1980s when recreational drug 42 
users were exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which 43 
metabolises to MPP+, a complex I inhibitor [10]. This was discovered to produce a 44 
Parkinsonian phenotype and nigral neuron loss [10]. Mitochondrial dysfunction has been 45 
observed in both sporadic and genetic forms of PD, as well as toxin-induced models of 46 
the disease. 47 
Sporadic PD 48 
Research by Schapira et al. (1989) found a decrease in complex I activity in PD 49 
substantia nigra tissue [11]. This decrease has been replicated in multiple studies [12±15]. 50 
Interestingly, this complex I deficiency in the substantia nigra appears to be specific to 51 
PD, as Multiple System Atrophy patients have normal levels of complex I activity [12]. 52 
Staining for complex I is variable across the substantia nigra, however PD patients have 53 
a higher proportion of neurons showing reduced complex I staining [16]. Complex I is the 54 
largest mitochondrial complex containing at least 44 subunits, 7 of which are encoded 55 
by mtDNA. The complex transfers electrons from NADH to ubiquinone and translocates 56 
protons across the mitochondrial inner membrane [17±19]. Consequences of impaired 57 
complex I function include; reduced ATP levels, reactive oxygen species (ROS) 58 
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generation, and impaired mitochondrial membrane potential (MMP) leading to calcium-59 
mediated damage [20].  60 
Early studies used samples from patients who had taken levodopa and other PD 61 
medications, therefore it is important to show that the complex I deficiency is not a 62 
secondary effect of the medication. Platelet samples were collected in a three-phase 63 
trial after no medication, after 1-month of carbidopa/levodopa treatment, and after 1-64 
month of carbidopa/levodopa plus selegiline treatment. No changes were observed in 65 
complex I, II/III or IV activity after each treatment [21]. This suggests that not only are 66 
mitochondrial deficiencies present before drug treatment, but also that the current 67 
medications do not improve these mitochondrial abnormalities in peripheral tissue. 68 
Therefore, it is plausible to hypothesise that targeting mitochondrial function 69 
therapeutically would be beneficial.    70 
Although a reduction in complex I activity has been consistently observed in substantia 71 
nigra tissue, mitochondrial complex activity has more differing results in non-CNS 72 
tissues such as skeletal muscle, platelets, lymphocytes and fibroblasts [22±27]. 73 
Deficiencies shown in other mitochondrial complexes have also been variable. This may 74 
be due to disease heterogeneity and the different methodologies used between studies, 75 
such as the purification of the mitochondria. The importance of mitochondrial purification 76 
has been highlighted by research showing an increasingly significant reduction in 77 
complex I activity in PD prefrontal cortex tissue throughout the purification process [28]. 78 
Interestingly, although the majority of evidence shows a decrease in complex I activity, 79 
blue native gel electrophoresis has shown that protein levels of complex I are 80 
unchanged [29]. This suggests that the decrease in activity is not due to reduced levels 81 
of complex I, but perhaps due to the modification of its enzymatic properties. It has also 82 
been suggested that oxidatively damaged subunits of complex I, lead to misassembly of 83 
the complex, and may contribute to its deficiency [30]. However, others have investigated 84 
a direct link between complex I deficiency caused by mtDNA changes and 85 
parkinsonism; this resulted in no association [31]. This calls into question how complex I 86 
(and others) deficiency is caused and if it is a primary or secondary consequence of 87 
disease; which is particularly important when targeting it for novel therapeutics.  88 
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Oxidative damage may also affect mtDNA, which is particularly susceptible due its 89 
proximity to the ROS produced by the mitochondrial complexes [32]. Research has 90 
shown that levels of oxidised coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine are 91 
elevated in the cerebral spinal fluid of sporadic PD patients, which may lead to this 92 
damage [33]. Several studies have investigated mtDNA with relation to ParkinsRQ¶V93 
Many have found somatic mutations accruing over the SDWLHQW¶V lifetime to be an 94 
important feature of PD, whilst other studies have investigated the role of inherited 95 
variation in mtDNA and PD. When considering somatic variation; post-mortem nigral 96 
neurons were found to exhibit mtDNA damage in PD patients, as opposed to cortical 97 
neurons, which are unaffected [34]. During healthy ageing the mtDNA copy number 98 
increases in response to mtDNA deletions increasing, whilst this increase in mtDNA 99 
copy number is not seen in those with PD, suggesting impaired mtDNA homeostasis [35]. 100 
Several studies have found an increase in mtDNA deletions in substantia nigra from PD 101 
patients compared to other brain regions and controls [36±38]. Furthermore, cholinergic 102 
neurons from the pedunculopontine nucleus were seen to have significantly increased 103 
mtDNA deletions, as well as increased mtDNA copy number in PD patients compared to 104 
controls [39]. This recent study calls into question the relative role of mtDNA in different 105 
brain regions, an under researched area, where there is still much to be learned from 106 
the relative mtDNA copy number and build-up of mtDNA deletions with age in relation to 107 
PD. 108 
Further research has shown increases in mtDNA somatic point mutations, particularly in 109 
complex IV encoding genes [40]. This was the largest study of acquired mtDNA 110 
mutations in post-mortem PD patient tissue and was not limited to one brain region. 111 
Interestingly, myocyte enhancer factor 2 D (MEF2D), which binds to mtDNA, might also 112 
be affected in PD. MEF2D binds to the section of mtDNA encoding for the complex I 113 
subunit NADH dehydrogenase 6 (ND6). If blocked, this leads to reduced complex I 114 
activity, increased H2O2 and reduced ATP levels [41]. Both reduced MEFD2 and ND6 115 
levels have been observed in post-mortem PD brain tissue [41].  116 
There is some debate within the literature as to the association of inherited variation in 117 
mtDNA with PD. Many studies report that haplogroups J and K confer a reduced risk of 118 
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PD in various European populations [42±44]. However, in an Australian population, neither 119 
haplogroup J nor K was seen to be protective [45]. Furthermore, a two-stage association 120 
study showed no association between any of the common European haplogroups and 121 
PD, but a meta-analysis did show a reduced risk with haplogroups J, K and T and 122 
super-haplogroup JT, as well as an increased risk with super-haplogroup HV [46]. Many 123 
of the above studies have undertaken the haplogroup association method which was 124 
also utilised to find an association between particular haplogroups (UKJT) and age at 125 
onset of PD [47]. Additional controversy is introduced when investigating mtDNA 126 
haplogroups and PD associations in different populations, as this can reveal very 127 
different results [48,49]. As more sophisticated techniques become available, such as 128 
mutational load analysis rather than association studies; these associations between 129 
mtDNA haplogroup and PD will become clearer and enable determination of less 130 
frequent variants. 131 
As well as functional changes, studies using patient-derived cells from idiopathic PD 132 
patients also exhibit alterations in mitochondrial morphology. Post-mortem PD caudate 133 
nucleus and skeletal muscle tissue has shown increased variability in mitochondrial 134 
morphology compared with healthy controls [50,51]. Additional studies using cellular 135 
models of sporadic PD have also shown alterations in mitochondrial morphology. 136 
Cytoplasmic hybrid (cybrid) cells are cells in which human neuroblastoma cells (SH-137 
SY5Y) deficient in mtDNA through ethidium bromide exposure are re-populated with 138 
mitochondria from sporadic PD patients. These have shown enlarged and swollen 139 
mitochondria, with a lower distribution of cristae compared to cybrid cells created using 140 
healthy control mitochondria [52]. Cybrid lines containing mitochondria from sporadic PD 141 
patients also have reduced MMP and defects in mitochondrial transport, as well as 142 
decreased complex I activity and increased ROS [52,53]. However, others using this 143 
technique have not found transmission of mitochondrial abnormalities into the resulting 144 
cybrids with mtDNA [54]. Furthermore, even in studies identifying transmission of the 145 
mitochondrial phenotype, authors did not find any deleterious mtDNA changes to which 146 
this phenotype could be attributed [52,53]; indicating further work is required in this area. 147 
Peripheral tissues from sporadic PD patients, such as fibroblasts, also show 148 
mitochondrial morphology impairments [55]. Neurons derived from sporadic PD patient 149 
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fibroblasts can now be generated using induced pluripotent stem cell (iPSC) 150 
technologies. Thus far, these have validated the post-mortem and peripheral tissue data 151 
showing alterations in mitochondrial function and morphology. For example, Hseih et al. 152 
(2016) used iPSC-derived neurons to show a decrease in mitochondrial motility [56]. 153 
 154 
Familial PD 155 
Although sporadic cases account for the majority of PD, around 10% of cases are 156 
familial [57]. Various models have been developed to study familial PD, such as the use 157 
of patient fibroblasts, knock-out Drosophila and mice, and iPSC-derived patient 158 
neurons. Familial PD models are often less heterogenous than sporadic PD models, 159 
due to their specific genetic causes. Therefore, they are highly suited to both studying 160 
mitochondrial dysfunction and testing potential therapeutics. These range from specific 161 
Leucine-rich repeat kinase 2 (LRRK2) inhibitors, to large scale drug repurposing studies 162 
[58,59]
. It is beyond the scope of this review to in detail go through the known familial 163 
causes of PD; therefore we will concentrate on two genetic types which have clear 164 
mitochondrial connections, LRRK2 and parkin/PINK1. Other genetic causes of PD such 165 
as alpha-synuclein have also been linked to mitochondrial function, however are beyond 166 
the scope of this review and are reviewed elsewhere [60]. 167 
LRRK2 168 
LRRK2 mutations are the most common genetic cause of PD, with the most common 169 
mutations being a glycine to serine substitution *6LQ/55.¶VNLQDVHGRPDLQ170 
which increases kinase activity [61]. Autosomal dominant mutations can lead to late-171 
onset PD, with polymorphisms in LRRK2 also being a risk factor for sporadic PD [62]. 172 
The normal function of LRRK2 seems to be complex, and is cell type specific. Various 173 
studies have found a role of LRRK2 in multiple fundamental cellular processes including 174 
cytoskeletal maintenance, autophagy and the immune response [61]. For instance, 175 
LRRK2 is highly expressed in human immune cells, and LRRK2 levels are increased in 176 
both innate and adaptive immune cells in sporadic PD patients [63]. LRRK2 variants in 177 
the same alleles DV3'LQIOXHQFHULVNIRUWKHLQIODPPDWRU\ERZHOGLVHDVH&URKQ¶V178 
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disease, adding to evidence linking PD, the gut, and inflammation [64]. For example, 179 
recent evidence has shown differences in colonic microbiota and microbiota metabolism 180 
in sporadic PD, which could potentially be a biomarker for the disease [65]. LRRK2 also 181 
has an important role in autophagy and the endolysosomal system. A large scale 182 
phosphoproteomics study revealed that LRRK2 regulates a subset of Rab GTPases 183 
and identified several endogenous substrates of LRRK2 [66]. In the two years since this 184 
discovery many more studies have gone on to investigate the interaction with Rab 185 
GTPases and LRRK2, and how this is affected by mutations in LRRK2. Rab GTPases 186 
are integral to membrane and vesicular trafficking, for example, Rab8a is important for 187 
the fusion and enlargement of lipid droplets [67]. Dysregulation of Rab35 phosphorylation 188 
has also been shown to cause neurotoxicity in vivo [68]. Additionally, disruptions in 189 
lysosome function and morphology have been shown in primary cortical neurons from 190 
G2019S mutant mice [69]. LRRK2 G2019S overexpression produces enlarged 191 
lysosomes with reduced degradative capacity [70]. Altered LRRK2 function could 192 
negatively influence autophagy and the endolysosomal system, leading to an 193 
accumulation of defective mitochondria. However, LRRK2 has also been found at the 194 
mitochondrial outer membrane [71], raising the possibility of a more direct role in 195 
mitochondrial function. 196 
With relation to mitochondrial function and morphology; LRRK2 models show some 197 
similarities and some differences to sporadic PD. LRRK2 G2019S mutant patient 198 
derived fibroblasts show reductions in MMP and cellular ATP levels, however they are 199 
distinct from sporadic PD as they show decreased activity in mitochondrial complexes III 200 
and IV, as opposed to complex I [72]. LRRK2 G2019S knock-in mice also show 201 
differences in mitochondrial complexes, with complex V subunit ATP5A and complex III 202 
subunit UQCR2 protein expression increasing in heterozygous mice [73]. LRRK2 does 203 
seem to have variable effects on mitochondrial function, with some cell types and 204 
studies reporting increased mitochondrial respiration [74], whilst others have reported 205 
decreased mitochondrial respiration [72,75]. However, these differences may be due to 206 
the media conditions under which the cells were grown, with some studies utilising 207 
µQRUPDO¶FXOWXUHPHGLXPDQGRWKHUVXWLOLVLQJPHGLDZLWKVXEVWUDWHVIRUFLQJXVHRI208 
oxidative phosphorylation [76]. Alterations in mitochondrial morphology may be 209 
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influenced by an interaction between the mitochondrial fission factor, dynamin-related 210 
protein 1 (Drp1), and LRRK2 [77±79]. Evidence shows that in LRRK2 G2019S knock-in 211 
mice there are mitochondrial abnormalities which correspond with an arrest in 212 
mitochondrial fission [73], as well as similar morphology to that observed in patient 213 
LRRK2 G2019S fibroblasts [75]. 214 
As discussed above, mitochondria are a major source of ROS in the cell; the 215 
detrimental effect of ROS throughout the cell, and specifically in PD, is well 216 
documented. However, more recent studies show the need to dissect the ROS pathway 217 
in more detail than is currently known. ROS are now known to be important signalling 218 
molecules in their own right, rather than simply being destructive to the cell [80]. Their 219 
role in PD may be more complex than previously thought, and similar to many other 220 
pathways, they may have a protective role which switches at a point in disease 221 
progression to being detrimental to the cell. Similar to sporadic PD, familial models also 222 
show an increase in ROS and their detrimental effects on proteins and DNA. LRRK2 223 
has been suggested to interact with peroxiredoxin 3 (PRDX3), a mitochondrial 224 
DQWLR[LGDQWSURWHLQDQGPXWDWLRQVLQ/55.FRXOGDIIHFW35';¶VDELOLW\WRVFDYHQJH225 
ROS [81]. Another link between the cells ability to control ROS production and 226 
mitochondrial function to maintain cellular energy levels are the uncoupling proteins 227 
(UCPs). It is proposed that the upregulation of UCPs, which transport hydrogen ions 228 
into the mitochondrial intermembrane space, may be a compensatory mechanism to 229 
protect against mitochondrial ROS levels [82]. Interestingly, UCP2 and UCP4 mRNA 230 
expression is upregulated in LRRK2 G2019S mutant fibroblasts and SH-SY5Y cells, 231 
respectively [74,82]. Current knowledge lacks the full understanding of how mutant 232 
LRRK2 causes mitochondrial alterations. Some of the outstanding questions are; is this 233 
a cell type specific effect and do all LRRK2 mutations have the same affect? However, 234 
that there are mitochondrial abnormalities present in LRRK2 mutant cells and tissue is 235 
clear and therefore this represents a viable therapeutic target. An unanswered question 236 
remains if the LRRK2 kinase inhibitors which are being developed will also have 237 
beneficial effects on mitochondrial function? 238 
Parkin and PINK1 239 
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Autosomal recessive mutations in PINK1 and Parkin are causative for early-onset PD. 240 
PINK1 is a kinase which is constitutively recycled at the mitochondrial outer membrane; 241 
whereas parkin is an E3 ubiquitin ligase which can be recruited to dysfunctional 242 
mitochondria. Both parkin and PINK1 have been found to have a crucial role in  243 
mitophagy. Mitophagy is the process by which damaged mitochondria are recycled; this 244 
is an area of intense study with new mitophagy pathways being elucidated by novel 245 
research in various cell types and under different conditions. The most well studied 246 
mitophagy pathway is dependent on parkin and PINK1 function; which has been 247 
extensively studied in vitro stress-induced situations. These pathways are reviewed 248 
elsewhere [83]; here we will focus on the evidence for mitophagy abnormalities in 249 
parkin/PINK1 systems which pertain to PD. Much of the PINK1/parkin dependent 250 
mitophagy has been delineated in cell lines overexpressing WT parkin with 251 
mitochondrial dysfunction induced by global dissipation of the MMP [84±87] and has been 252 
reviewed elsewhere [88]. Recent in vivo evidence has suggested that PINK1/parkin 253 
mitophagy pathway is not well utilised in many tissue types. McWilliams et al. (2016) 254 
developed a mouse model utilising the mito-QC constructs in order to study in vivo 255 
mitophagy in a variety of tissues [89]. Further to this work they generated a mito-QC 256 
mouse on a PINK1 K/O background, enabling them to study PINK1 dependent 257 
mitophagy in vivo in a variety of tissues. This work found that basal mitophagy rates 258 
were comparable between WT and PINK1 K/O mice in a variety of tissues including the 259 
dopaminergic system. Furthermore, they identified variations in mitophagy rates 260 
dependent on the energy status of the tissue selected and studied [90]. The lack of an 261 
effect of defects in parkin/PINK1 on basal mitophagy in vivo was provided by the recent 262 
studies in Drosophila models [91]. This work raises the issue of the in vivo relevance of 263 
PINK1/parkin mitophagy under normal conditions and raises the possibility that this 264 
pathway is utilised in a cell type and stress type specific manner. Further work is 265 
needed to fully establish the mechanisms of mitophagy which are utilised by the aged 266 
dopaminergic system, as well as other tissues affected in PD.  267 
The mitophagy pathway and the role of parkin/PINK1 is extensively studied as 268 
discussed above, however, an alternative pathway has also been implicated in 269 
parkin/PINK1 PD. This pathway is the degradation of mitochondrial components via 270 
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mitochondrial derived vesicles (MDV). Recent work provided a link between the MDV 271 
pathway directly to lysosomes and immune/autoimmune responses in PD [92]. This work 272 
showed that it is not only in response to stress that the MDV pathway can mediate 273 
mitochondrial antigen presentation (MitAP) on the cell surface via major 274 
histocompatibility class (MHC) one molecules. Usually, antigens are processed to 275 
peptides and presented via MHC by processing of the proteasome system. However, 276 
Matheoud et al. (2016) VKRZHGWKLVZDVDOVRSRVVLEOHYLD0'9¶VF\FOLQJWKURXJKWKH277 
lysosome [92]. The team also identified that PINK1/parkin functions as a brake on this 278 
pathway. Therefore, without functional PINK1/parkin, 0'9¶VZRXOGEHDYDLODEOHWREH279 
processed by the lysosome to peptides and presented as MitAP via MHC on the cell 280 
surface, leading to an immune response. The exact role of PINK1/parkin in this pathway 281 
is still to be elucidated, however, the MDV pathway to MitAP was shown to be sorting 282 
nexin 9 (Snx9) dependent [92].  283 
An area well studied in relation to both PINK1 and parkin mutants is the presence of 284 
mitochondrial dysfunction in PINK1 and parkin mutant or knock-down models and 285 
patient tissue. Similar to sporadic PD, Parkin mutants show a decrease in mitochondrial 286 
complex I activity and a decrease in both MMP and cellular ATP levels. This has been 287 
evidenced in both fibroblasts derived from PD patients with parkin mutations [93], parkin 288 
knockdown zebrafish embryos [94] and parkin knockout Drosophila models [95]. 289 
Furthermore, Pink1 mutant zebrafish show decreases in mitochondrial complex I and III 290 
activity [96]. Both parkin and PINK1 mutant patient cells, and cell/animal models have 291 
reduced mitochondrial respiration [93,97±99]. Mitochondrial morphological abnormalities 292 
have also been reported in both parkin and PINK1 patient cells and models, however 293 
both elongation and fragmentation of the mitochondrial network has been observed. 294 
Many of these apparently disparate findings occur when comparisons are made 295 
between endogenous parkin or PINK1 expression versus overexpression, or the cell 296 
culture media conditions vary, enabling the cells to utilise glycolysis or oxidative 297 
phosphorylation to predominantly meet the cells energy requirements.  298 
As more work is undertaken in physiologically relevant models; a complex system is 299 
HOXFLGDWHGFRPELQLQJUROHVIRU3,1.SDUNLQLQPLWRSKDJ\0'9¶VDQG0LW$3300 
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mitochondrial dysfunction and morphology. Exactly what the major pathway is which 301 
triggers cell death in PD remains elusive; with more work needed in both in vivo models 302 
and cell models without over expression of PINK1/parkin. 303 
Toxin-induced models 304 
Toxin-induced models have been invaluable in studying mitochondrial alterations in PD. 305 
6-hydroxydopamine (6-OHDA) was the first toxin PD model to be developed. 6-2+'$¶V306 
structure is similar to dopamine, but with an additional hydroxyl group which leads to 307 
oxidative stress in dopaminergic neurons [100]. Mice and rats treated with 6-OHDA show 308 
the typical motor defects associated with PD but Lewy bodies are not present [101].  309 
MPTP-induced PD models are also commonly used, and were first developed using 310 
non-human primates [102]. These respond to typical PD medication, such as Levodopa, 311 
VKRZLQJWKHPRGHO¶VFOLQLFDOXWLOLW\LQGHYHORSLQJWKHUDSHXWLFV [100]. Since then, MPTP 312 
has been utilised in mice [103], C.elegans [104], and zebrafish models of PD [105]. MPTP 313 
can cross the blood brain barrier (BBB), where it is metabolised by monoamine oxidase 314 
B and forms MPP+, its toxic metabolite. MPP+ enters dopaminergic neurons through 315 
dopamine transporters, and inhibits mitochondrial complex I, leading to decreased ATP 316 
levels and increased ROS [100]. Interestingly, rats appear to be resistant to MPTP 317 
toxicity, due to their high levels of monoamine oxidase at the BBB, which converts 318 
MPTP to MPP+. MPP+ is less readily permeable to the brain compared to MPTP, thus 319 
conferring this resistance [100]. MPTP-induced models will typically mimic late-stage PD, 320 
but not Lewy body pathology. Dopaminergic neuron loss can be altered though different 321 
numbers of doses and frequency, though the loss is not progressive [100]. 322 
The pesticide rotenone is another complex I inhibitor, which can cross the BBB and 323 
cellular membranes to enter the mitochondria [100]. Chronic systemic infusion in rats 324 
causes degeneration of dopaminergic neurons, as well as Lewy body-like pathology, 325 
which is not seen in other toxin-induced models [106]. However, the reproducibility of 326 
rotenone induced dopaminergic loss is low, and there is a high mortality rate [107]. The 327 
herbicide paraquat has a very similar structure to MPP+, causes nigral cell loss, and is 328 
frequently used in PD models [100]. Paraquat causes redox recycling which yields ROS, 329 
principally in the mitochondria [100]. There is epidemiological evidence showing that 330 
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exposure to pesticides/herbicides, such as rotenone and paraquat, are a risk factor for 331 
PD [108].  332 
The above animal models focus on recapitulating the loss of dopaminergic neurons 333 
from the substantia nigra; a recent animal model however, has concentrated on the 334 
cholinergic system in PD  [109,110]. This model utilises stereotactic injection of lactocystin 335 
in the substantia nigra pars compacta, however the authors then concentrate on 336 
investigating the effects on the pedunculopontine nucleus, an area which is a promising 337 
target for therapy via deep brain stimulation [111]. 338 
Overall, mitochondrial dysfunction in PD has been implicated in multiple models, 339 
including post-mortem tissue, animal models, and iPSC-derived neurons. These 340 
changes, such as reductions in complex I activity and increased ROS, have been 341 
evidenced in both familial and sporadic forms of the disease. Targeting these specific 342 
changes in mitochondrial function and morphology, such as complex I activity or Drp1-343 
mediated fission may be essential in the development of therapeutics for PD. 344 
 345 
0LWRFKRQGULDODOWHUDWLRQVLQ$O]KHLPHU¶VGLVHDVH 346 
$O]KHLPHU¶VGLVHDVH$'LVDSURJUHVVLYHLQFXUDEOHQeurodegenerative disease, and 347 
the most common cause of dementia worldwide [112]. Common symptoms include a 348 
decline in cognitive function, as well as behavioural symptoms such as depression and 349 
apathy [113]. Neuropathology of AD is defined by the presence of extracellular plaques 350 
FRPSRVHGRIDP\ORLGEHWD$ȕDQGLQWUDFHOOXODUQHXURILEULOODU\WDQJOHVFRQWDLQLQJ tau, 351 
with profound neuronal loss occurring later in the disease course.  352 
The Amyloid Cascade Hypothesis was first proposed by Hardy and Higgins (1992), and 353 
VXJJHVWVWKDWWKHDFFXPXODWLRQRI$ȕLVWKHLQLWLDOFDXVHRI$'Sathology, with 354 
neurofibrillary tangles, atrophy and cognitive decline occurring as a direct result [114]. 355 
+RZHYHUWKHH[WHQWRI$ȕSDWKRORJ\SUHVHQWSRVW-mortem has not been found to 356 
correlate well with the clinical progression of the disease [115]. Furthermore, treatments 357 
which have targeted the neuropathology have consistently failed in clinical trials [116,117]. 358 
This suggests that there are other mechanisms which play a crucial role in the 359 
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progression of AD. One such mechanism is mitochondrial dysfunction, which has been 360 
indicated in both sporadic (sAD) and familial (fAD) AD, as well as toxin-induced models.  361 
 362 
Sporadic AD 363 
Mitochondrial function has been seen to be impaired in sAD; levels of ATP have been 364 
seen to be decreased in patient post-mortem tissue [118]. This finding has been 365 
replicated in peripheral patient tissue, including fibroblasts [119]. Many studies have 366 
found decreased activity of complex IV in sAD patients; in platelets [120±122], fibroblasts, 367 
[123]
 and post mortem tissue [124±126]. Complex IV deficiency has also been seen in 368 
patients with mild cognitive impairment (MCI) [127]. It has been proposed that mtDNA 369 
deletions, which accumulate with age, may be responsible for complex IV deficiency 370 
observed in AD [128]. Changes in mitochondrial genes can be seen early in disease 371 
progression in patient blood [129].  372 
Whilst some have suggested that deficiency is specific to complex IV [121,126], others 373 
have also seen deficiencies in other complexes. Reduced gene and protein expression 374 
of complex I has been seen [130,131], whilst Fisar et al. (2016) observed an increase in 375 
complex I activity in sAD platelets [122]. Complex III proteins have also been found to be 376 
reduced in AD [132], and recently Armand-Ugon et al. (2017) [133] found expression of 377 
subunits from all complexes to be decreased in the entorhinal cortex of AD patients 378 
post-mortem.  379 
As well as changes in mitochondrial function, alterations in mitochondrial morphology 380 
and distribution have been seen. Perez et al. (2017) found mitochondria in sAD 381 
fibroblasts to be reduced in length [119], whilst Wang et al. (2008) [134] saw an increase in 382 
the number of fragmented mitochondria. Mitochondria have also been seen to 383 
accumulate in the perinuclear region in sAD patient fibroblasts [134], indicating a collapse 384 
of the mitochondrial network. 385 
The processes of mitochondrial fusion and fission have also been seen to be impaired 386 
in sAD, with changes in the expression of key proteins noted [135±137]. Drp1, involved in 387 
mitochondrial fission, was found to be reduced in hippocampal post mortem samples of 388 
14 
 
sAD [136], a finding replicated in sAD patient fibroblasts [137] and lymphocytes [138]. Drp1 is 389 
usually found in the cytoplasm but is recruited to the outer mitochondrial membrane by 390 
mitochondrial fission protein (Fis1) and other receptors Mid49, Mff and Mid51, during 391 
fission. Localisation of Drp1 to the mitochondria has been found to be reduced [137], 392 
suggesting an impairment in the recruitment of Drp1. Drp1 has also been linked to AD 393 
pathology; it has been seen to co-ORFDOLVHZLWK$ȕUHVXOWLQJLQDEQRUPDOLQWHUDFWLRQV394 
which increase with disease progression [135]. Proteins involved in mitochondrial fusion, 395 
such as the mitofusins (Mfn1 and Mfn2) and optic atrophy (OPA1), have also been 396 
studied. Decreases in all three main fusion proteins have been seen in post-mortem 397 
patient tissue [135,136]. 398 
2[LGDWLYHVWUHVVKDVDOVREHHQVHHQWRSOD\DQLPSRUWDQWUROHLQ$O]KHLPHU¶VGLVHDVH399 
lipid peroxidation, protein oxidation and DNA oxidation have all been noted in AD as 400 
markers of oxidative damage [139]. The mitochondria are a key source of ROS. Damage 401 
to the mitochondria, including impairments in the electron transport chain and 402 
imbalanced fusion and fission, causes an increased level of ROS, which in turn can 403 
contribute to further mitochondrial damage [140]. Increased ROS levels have been noted 404 
in sAD fibroblasts [119], which showed an increased accumulation of 8-oxo-guanine, an 405 
indicator of oxidative DNA damage [141]. Furthermore, ROS produced by the 406 
PLWRFKRQGULDKDYHEHHQVHHQWRWULJJHUWKHDFFXPXODWLRQRI$ȕ[142].  407 
 408 
Familial AD 409 
A small percentage of AD is caused by mutations in the presenilin 1 (PSEN1), presenilin 410 
2 (PSEN2) or amyloid precursor protein (APP) genes. PSEN1 and PSEN2 are localised 411 
to the mitochondrial associated membranes (MAMs) [143], whereas PSEN2 in particular 412 
modulates Ca2+ uptake across the endoplasmic reticulum and the mitochondria [144]. 413 
PSEN2 overexpression has been seen to increase the interaction between the two 414 
organelles, leading to increased mitochondrial Ca2+ uptake [144].  415 
As in sAD, mitochondrial dysfunction has been indicated in genetic forms of AD. 416 
Decreased levels of ATP have been seen in various transgenic mouse models 417 
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[140,145,146]
, and in fibroblasts from patients with a PSEN1 mutation [147]. These fibroblasts 418 
were also found to show reduced basal and maximal respiration [147]. In PSEN2 419 
knockout mouse embryonic fibroblasts (MEFs), impaired respiratory capacity is seen, 420 
with reductions in basal oxygen consumption and spare capacity; a balance towards 421 
glycolysis is also noted [148]. Interestingly, respiratory function was restored when human 422 
PSEN2 was expressed on the knock-out background, suggesting a key role for PSEN2 423 
in mitochondrial function [148]. As well as decreased ATP levels, various genetic models 424 
of fAD have shown reduced MMP, including M17 neuroblastoma cells overexpressing 425 
APP [149] and transgenic mouse models [140,150].  426 
Mitochondrial morphology is also affected in fAD. PSEN1 fibroblasts have been seen to 427 
have a reduced number of mitochondria [147]. Mitochondria of PSEN2 knockout MEFs 428 
have been seen to have less defined cristae [148]; damaged cristae have also been 429 
observed in an APP transgenic mouse model [151]. As is also seen in sAD, mitochondria 430 
localise around the nucleus in genetic AD models [149].  431 
Mitochondrial quality control mechanisms have also been studied in fAD. For example, 432 
mitochondrial transport has been found to be impaired in several fAD mouse models. 433 
Anterograde movement is impaired in an APP mouse model [151], whilst both retrograde 434 
and anterograde transport have been seen to be impaired in PSEN1 and APP/PSEN1 435 
mouse models [152]. Trushina et al. (2012) also noted that neurons with impaired 436 
mitochondrial transport were more susceptible to excitotoxic cell death [152]. Another 437 
important process in regulating mitochondrial quality control is mitophagy. An 438 
accumulation of damaged mitochondria is often seen in AD, suggesting an impairment 439 
in mitophagy. Recently, mitophagy has been studied in PSEN1 patient fibroblasts and 440 
iPSC-derived neurons with the same mutation. In both fibroblasts and iPSC-derived 441 
neurons, mitochondrial localisation of parkin was seen, suggesting that mitochondria 442 
were labelled correctly but unable to be degraded. A reduction in the degradation stage 443 
of autophagy was proposed, to account for the accumulation of damaged mitochondria 444 
[153]
.  445 
Similar to sAD, increased oxidative stress has been indicated in fAD. Increased ROS 446 
levels have been observed in several fAD transgenic mouse models [140,146,150]. 447 
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Increased oxidative DNA damage has also been seen in mice expressing mutated APP 448 
from 6 months of age, becoming more pronounced at 24 months [150]. Interestingly, fAD 449 
lymphocytes have been seen to respond differently to oxidative stress than sAD 450 
lymphocytes. When treated with 2-deoxy-D-ribose (2dRib), which induces oxidative 451 
stress, PSEN1 cells proved to be more resistant, with a lower rate of apoptosis and 452 
lower mitochondrial membrane depolarisation compared to sAD cells [154].  453 
 454 
Toxin induced models of AD 455 
As well as sAD and fAD, mitochondrial dysfunction is also seen in toxin-induced models 456 
of AD. Administration of scopolamine has been seen to induce several key features of 457 
$'LQFOXGLQJFRJQLWLYHLPSDLUPHQWVDQGWKHDFFXPXODWLRQRI$ȕ[155]. This model also 458 
exhibits increased oxidative stress [156,157], and mitochondria with a higher vulnerability 459 
to swelling and membrane potential dissipation [158].  460 
Another toxin induced model of AD is the administration of streptozotocin, which has 461 
been seen to induce cognitive impairments [159]DVZHOODVWKHDFFXPXODWLRQRIERWK$ȕ462 
and hyper-phosphorylated tau [160]. This model also demonstrates decreased activity of 463 
complex I [161] and complex IV [160], an increase in Drp1 protein expression [161], and 464 
decreased MMP [160].  465 
7UHDWPHQWZLWK$ȕDOVRLQGuces AD-OLNHSKHQRW\SHV&HOOVWUHDWHGZLWK$ȕVKRZ466 
mitochondrial defects, including a decrease in MMP, fragmentation of the mitochondria, 467 
and generation of ROS [162].  468 
There is a substantial amount of evidence showing mitochondrial dysfunction plays a 469 
key rROHLQ$O]KHLPHU¶VGLVHDVHLQERWKV$'DQGI$'DVZHOODVLQWR[LQLQGXFHG470 
models of AD. Alterations in mitochondrial function, as well as morphology and 471 
mechanisms of quality control, have been demonstrated in various models of AD. With 472 
many treatments focussed on the neuropathology of AD being unsuccessful, 473 
mitochondrial dysfunction provides a new target for the treatment of AD.  474 
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Mitochondrial targeted Antioxidants as a therapeutic strategy for 475 
neurodegeneration 476 
As outlined above, mitochondrial abnormalities are well characterised in both PD and 477 
AD. As a result, several approaches have been utilised to address the mitochondria as 478 
a therapeutic target. One of the major pathways harnessed by potential therapeutics is 479 
the antioxidant pathway.  Antioxidants are compounds that inhibit the oxidation of other 480 
molecules. Exogenous antioxidants, such as vitamins, carotenoids and flavonoids, 481 
obtained from the diet or synthetically have long been used to promote good health or 482 
as treatments. These antioxidants are often distributed ubiquitously throughout the body 483 
and typically localised predominantly in the cytosol [163]. However, antioxidant 484 
therapeutic strategies for PD and AD have focused on developing mitochondrial 485 
targeted antioxidants.  486 
One of the most studied mitochondrially targeted antioxidant compounds is mitoquinone 487 
(MitoQ), consisting of a modified ubiquinone conjugated to a triphenylphosphonium 488 
(TPP). TPP conjugation is a comprehensively established approach to develop 489 
mitochondrial targeted species [164]. Physiochemical factors allow for TPP conjugated 490 
compounds to directly penetrate lipid bilayers and accumulate at the negatively charged 491 
mitochondrial membrane [164]. MitoQ exerts direct antioxidant action by scavenging 492 
superoxide, peroxyl, and peroxynitrite ROS [164]. Furthermore, once oxidised, MitoQ is 493 
continually recycled to its antioxidant ubiquinol form [164]. MitoQ has also been found to 494 
be protective in both MPP+ and 6-OHDA toxin induced PD in in vitro experiments. MitoQ 495 
reduces mitochondrial fragmentation and translocation of Bax when used to pre-treat 496 
SH-SY5Y neuroblastoma cells exposed to 50 µM of 6-OHDA [165]. Furthermore, MitoQ 497 
treatment of MPTP treated N27 cells reduces toxicity, improves MMP and reduces 498 
apoptotic markers. Treatment of MPTP exposed mice with MitoQ reversed the loss of 499 
tyrsosine hydroxylase and MMP and reduced the activation of caspase 3. Additionally, 500 
this treatment regime translated into improved motor function [166]. The numerous 501 
studies of MitoQ both in vitro and in vivo models of PD led to MitoQ being tested in a 502 
clinical trial for PD. Unfortunately, MitoQ failed to show any therapeutic effect in a 128 503 
patient double blind 12 month human trial at either 40 mg and 80 mg per day dose [167]. 504 
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However, MitoQ was shown to be effective in a clinical trial preventing liver damage in 505 
hepatitis C patients [168]. 506 
MitoQ has also been tested in both in vitro and in vivo models of AD. N2a cells pre-507 
WUHDWHGZLWK0LWR4VKRZHGUHGXFHGK\GURJHQSHUR[LGHOHYHOVDIWHU$ȕWUHDWPHQWXQGHU508 
these conditions ATP levels and MMP were also shown to be improved [169]. In a 509 
transgenic mouse model expressing three human mutant genes of APP, PSEN1, and 510 
tau, the treatment with MitoQ showed an improved behavioural phenotype[170]. 511 
Additionally, isolated MitoQ treated transgenic mice brains showed reduced lipid 512 
peroxidation (an indicator of ROS exposure)UHGXFHG$ȕEXUGen and reduced caspase 513 
activation. 514 
Skulachev (SkQ1) antioxidants are similar to MitoQ, however they involve the use of 515 
conjugated mitochondrial targeted motifs, like rhodamine and TPP, to plastiquinone [171].  516 
Much like ubiquinone, plastiquinone acts as an antioxidant by quenching superoxide. 517 
Using a rat model with an inherited over production of free radicals that present AD like 518 
pathology (OXYS model), SkQ1 supplemented via the diet was found to accumulate in 519 
neuronal mitochondria [172]. Furthermore, 6N4VXSSOHPHQWDWLRQUHGXFHV$ȕOHYHOVDQG520 
tau hyperphosporylation in addition to improving memory and learning behaviours 521 
[172,173]
. 522 
MitoApo, similarly to MitoQ, is a TPP conjugated form of the organic compound 523 
apocynin. Apocynin is an inhibitor NADPH oxidase and thereby acts as an antioxidant 524 
by preventing NADPH oxidase from converting O2 into superoxide. MitoApo has been 525 
found to protect primary cortical neurons against peroxide shock, in addition to 526 
protection from 6-OHDA treatment in Lund Human Mesencephalic (LUHMES) cells [174]. 527 
In a preclinical animal model of PD, MitoApo exhibited strong neuroprotective effects 528 
against MPP+, attenuating glial cell activation and improving motor function [175]. 529 
Melatonin is a direct scavenger of many ROS species; hydroxyls, peroxyls, free 530 
radicals, peroxylnitrites and other nitrous oxides under physiological conditions [176]. This 531 
direct ROS scavenging action, coupled with evidence that melatonin is mitochondrially 532 
localised [177], makes melatonin an attractive mitochondrial therapy for 533 
neurodegenerative diseases. Melatonin is also produced endogenously, therefore the 534 
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direct antioxidant effect of melatonin is enhanced by its ability to induce antioxidant 535 
enzymes, such as superoxide dismutase (SOD) and glutathione (GSH), and inhibit the 536 
action of many pro-oxidant pathways [178]. In a 6-OHDA lesion rodent model, treatment 537 
with melatonin for 7 days via osmotic pump ameliorated the reduced respiratory chain 538 
enzymes activity in nigral tissue, in addition to improving motor behaviour. Co-539 
administration of melatonin with MPTP in a mouse model abolished any dopaminergic 540 
cell loss [179]. 541 
0HODWRQLQKDVEHHQVKRZQWRLQKLELW$ȕLQGXFHG526SURGXFWLRQin vivo$ȕ-induced 542 
phospholipid damage was shown to be mitigated by melatonin treatment [180]. In 543 
mitochondria isolated from APP/PSEN1 transgenic mice, treatment with melatonin 544 
UHGXFHG$ȕOHYHOVDQGLPSURYHGMMP and ATP production [181].  545 
Peptide strategies 546 
Outside of the TPP conjugation strategy for creating mitochondrial targeting 547 
compounds, Sezto-Schiller (SS) tetrapeptides have been used to create mitochondrial 548 
targeted antioxidants. SS tetrapeptides contain an aromatic cationic sequence which 549 
produces preferential localisation to the inner mitochondrial membrane. However, this 550 
localisation method does not seem to be wholly based on the MMP. These SS 551 
tetrapeptides have been studied in an MPTP treated mouse PD model [182] and were 552 
found to have neuro-protective properties. Mice pre-treated with SS-31 and SS20 half 553 
an hour before a series of MPTP intraperitoneal injections showed reduced dopamine 554 
depletion and greater survival of dopaminergic neurons in the substantia nigra pars 555 
compacta. Isolated mitochondria from the MPTP treated mice have reduced oxygen 556 
consumption and reduced ATP production; treatment with SS-31 and SS-20 attenuate 557 
these reductions [182]. Regarding AD models, SS-UHGXFHVWKHWR[LFLW\RI$ȕ$ȕ558 
toxicity in N2a cells causes reduced ATP and MMP, and increased ROS production; 559 
pre-treatment with SS-31 improves all of these parameters [169]. In addition, in N2a cells 560 
overexpressing APP, SS-31 improved neurite outgrowth [169].  561 
Strategies to manipulate mitochondrial quality control and dynamics 562 
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As outlined above, alterations in mitochondrial morphology and dynamics are features 563 
of several PD and AD models and patient tissue. As a result, attempts have been made 564 
to manipulate the mitochondrial quality control processes as therapeutic targets for AD 565 
and PD.  566 
Some familial forms of PD are caused by mutations in PINK1 which results in reduced 567 
kinase activity [183], . Kinetin, an adenosine  N6-furfuryladenine moiety, has been found 568 
to mirror PINK1 action, increasing Parkin recruitment to damaged mitochondria; which 569 
leads to reduced apoptosis in human derived dopaminergic neurons [184]. More recently, 570 
however, an in vivo study in an alpha synuclein rodent model found no positive effect of 571 
kinetin treatment [185].  572 
Kinetin was found to be neuro-protective in an AD model induced by aluminium chloride 573 
and D-galactose treatment [186]. Kinetin was co-administered with aluminium chloride 574 
and D-galactose at three doses. Wei et al. (2017) observed dose dependant activity 575 
with kinetin co-administration improving performance in Morris water maze [186]. This 576 
dose dependant effect also translated into increased activity of key antioxidant enzymes 577 
GSH, SOD and catalase (CAT). Furthermore, kinetin was shown to significantly reduce 578 
$ȕGHSRVLWLRQLQGXFHGE\WKHDOXPLQLXPFKORULGHDQG'-galactose treatment [186]. Whilst 579 
the specific mechanism of kinetin has yet to be elucidated, this research raises key 580 
insights to the neuroprotective effects of increased mitophagy. 581 
Drp1 inhibitors have been explored as a therapeutic avenue in both PD and AD. Mdivi-582 
1, mitochondrial division inhibitor 1, is a quinazolinone that allosterically binds to Drp1 583 
and prevents the self-assembly of ring structures by inhibiting GTPase activity; therefore 584 
reducing the fission activity of Drp1 [187]. Mdivi-1 improves dopamine release and 585 
neuronal survival in an in vivo MPTP mouse model [188]. In an A53T-alpha- synuclein rat 586 
model of PD, mdivi-1 treatment prevented motor defects and loss of neurons [189]. 587 
Furthermore, mdivi-1 reduced mitochondrial fragmentation and lipid peroxidation, in 588 
addition to significantly improving the mitochondrial spare respiratory capacity in 589 
isolated A53T synaptosomes [189]. Recently, the ability of mdivi-1 to effect mitochondrial 590 
morphology has been called into question with alternative mechanisms being identified 591 
therefore the mdivi-1 literature must be interpreted with caution[190]. Curiously, Bordt et 592 
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al. (2017) failed to observe any mitochondrial morphology effects in primary neurons 593 
and COS-7 cells but verified that mdivi-1 was an inhibitor, although weakly (Ki>1.2mM), 594 
of the GTPase activity of Drp1 [190]. Furthermore, in this study Bordt et al. (2017) report 595 
that mdivi-1 acts as a reversible complex I inhibitor at concentrations greater than 25 596 
ȝM in primary neurons by a yet to be elucidated mechanism. Whilst Bordt et al. (2017) 597 
raise a valid caution of the use of mdivi-1, most of published data using mdivi-1 reports 598 
it as an inhibitor of Drp1 as determined by analysis of mitochondrial morphology, with 599 
mdivi-1 being protective in PD and AD models [187±189]. Other compounds which inhibit 600 
Drp1 function have also been found to have protective effects in in vitro models [191]. 601 
Rationally designed peptides which inhibit 40% and 50% of the GTPase activity of Drp1 602 
have been used in an MPP+ in vitro model of PD [192]. The peptide P110 inhibited Drp1 603 
mitochondrial translocation in SH-SY5Y cells treated with MPP+ and CCCP [192]. 604 
Furthermore, P110 prevented an increase in the production of mitochondrial superoxide 605 
species and prevented a drop in the MMP upon exposure to MPP+ [192]. 606 
Mdivi-KDVEHHQVWXGLHGLQDQ$O]KHLPHU¶VF\EULGFHOOPRGHOin which SH-SY5Y cells 607 
are depleted of endogenous mtDNA and replaced with mitochondria from sporadic 608 
$O]KHLPHU¶VSDWLHQWV [193]. The SH-SY5Y cybrids have reduced ATP output and a highly 609 
fragmented mitochondrial network. Mdivi-1 treatment blocked mitochondrial 610 
fragmentation, improved ATP production, MMP, complex IV activity, and supressed 611 
ROS production [193]. Confirming a morphology effect of mdivi-1, the cybrids treated with 612 
mdivi-1 differed morphologically from the untreated cybrids in having longer and denser 613 
PLWRFKRQGULD,Q1DQHXURQDOFXOWXUHVH[SRVHGWR$ȕSHSWLGHWKHUHLVLQFUHDVHG614 
production of hydrogen peroxide, whilst the mdivi-1 pre-treated and post-treated cells 615 
reduced hydrogen peroxide production to control levels [194]. The mdivi-1 treated cells 616 
also showed improved ATP production and cell viability. The effects of mdivi-1 have 617 
also been explored in vivo in CRND8 mice, an amyloid precursor line [195]. Primary 618 
neuronal cultures from CRND8 mice treated with mdivi-1 showed significantly reduced 619 
amount of fractured mitochondria and increased MMP and ATP output [195]. The mice 620 
rapidly acquire amyloid pathology impairments in their behaviour; dosing with mdivi-1 621 
improved behaviour in the spontaneous alteration task in a Y-maze apparatus [195]. 622 
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On review, it seems that Drp1 inhibition-based therapies may seem promising but there 623 
are many caveats to be taken with such an approach. There is little understanding of 624 
the effects of chronic exposure of Drp1 modulating species or effects in off-target 625 
tissues. 626 
Deep brain stimulation strategies on mitochondrial disorders  627 
Deep brain stimulation (DBS) has emerged as a strategic surgical treatment for patients 628 
with PD and other movement disorders. Lately its application has been extended to a 629 
wider range of neuropsychiatric disorders. In 2016, Kim et al. observed that DBS of the 630 
nucleus accumbens in adrenocorticotropic hormone treated rats resulted in greater 631 
mitochondrial function compared to the untreated control [196]. This finding suggests that 632 
there is scope to use DBS directly to modulate mitochondrial function, however it exists 633 
as a monolith and an open exciting avenue of mitochondrial research. Clinically, DBS 634 
has been used with positive results on at least four patients with mitochondrial specific 635 
disorders. DBS was found to be beneficial in a 41 year old male with multiple mtDNA 636 
deletions leading to striatal necrosis [197]. The treatment was found to have persisting 637 
effect after two years [197]. In 2012, a 49 year old male with a rapidly progressive 638 
Parkinson-dystonia syndrome with multiple mtDNA deletions also responded well to 639 
DBS [198]. An immediate therapeutic effect was found with DBS treatment of a patient 640 
with mitochondrial encephalopathy which remained stable for three years [199]. Martinez-641 
Ramirez et al. (2016) reported a case of DBS treatment on a patient with a biopsy 642 
proven complex I deficiency suffering from myoclonus and dystonia [200]. The effect of 643 
the DBS treatment was immediate, with symptoms being improved six months after 644 
DBS, however, a regression was observed 12 months post-DBS.  Whilst these four 645 
case studies show promise in the treatment of mitochondrial disorders, it is unclear if 646 
the DBS was acting directly on the mitochondria of the patients. 647 
Phenotypic drug screens for compounds which improve mitochondria function 648 
Finally, we and others have carried out compound screens to identify compounds which 649 
improve mitochondrial function in PD and AD. We carried out the first compound screen 650 
in patient derived fibroblasts of PD patients (with parkin mutations) using MMP as the 651 
primary read out [59]. In a screening cascade which included secondary assays 652 
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investigating cellular ATP levels, toxicity screening, and expanded concentration 653 
response curves; we identified a group of compounds which improved mitochondrial 654 
function in parkin mutant patient fibroblasts [59]. A high proportion of these compounds 655 
had a common structural feature of a steroid backbone. Furthermore, we investigated 656 
the effect of two compounds on the individual activity of the respiratory chain enzymes, 657 
and found a large increase in the activity of all complexes; not just complex I, which is 658 
reduced in parkin mutant patient fibroblasts [59]. One of the compounds is already in 659 
clinical use for primary biliary cirrhosis, ursodeoxycholic acid (UDCA). Next, we 660 
investigated the effects of UDCA in other forms of PD; we found an increase in cellular 661 
ATP levels in fibroblasts from patients with G2019S LRRK2 mutations, as well as 662 
people who have the G2019S mutation and who do not yet have PD symptoms [72]. In 663 
this study, we also found a protective effect of UDCA in an in vivo Drosophila model of 664 
G2019S LRRK2 [72]. Others have also tested UDCA and the related compound TUDCA 665 
in PD models. TUDCA is protective in C. elegans models of PD [201]. UDCA treatment in 666 
a rat rotenone PD model was shown to normalise ATP content, increase striatal 667 
dopamine content, reduce expression of apoptotic markers and alter mitochondrial 668 
morphology by electron microscopy [202].  669 
Both UDCA and TUDCA have also been tested in AD models [203,204]. TUDCA treatment 670 
reduces apoptosis in AD mutant neuroblastoma cells via a p53 mechanism [203]. In two 671 
GLIIHUHQW$'PRXVHPRGHOV78'&$WUHDWPHQWUHGXFHV$ȕSDWKRORJ\DQGSUHYHQWV672 
cognitive impairment [204]. 673 
Phenotypic screens differ greatly from the classical compound screens undertaken by 674 
the pharmaceutical industry. Phenotypic screening has some advantages in that this 675 
can be performed in disease relevant models, such as patient derived cells, and may 676 
lead to the identification of many compounds with the ability to modulate a particular 677 
pathway; for example, those associated with the mitochondria. The difficulty is then 678 
being able to identify the target by which the compound is positively modulating the 679 
pathway. If successful, however, this can lead to the identification of novel therapeutic 680 
targets which can then be screened in a more classical way. Figure 1 outlines an 681 
example pathway of how a phenotypic screen could be undertaken and how the 682 
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successful drug candidates could be taken forward through the drug discovery pipeline. 683 
Phenotypic screening is being utilised more often by academic groups with expertise in 684 
the complex biology and models which are required to make phenotypic screening as 685 
beneficial as possible. In light of the literature surrounding the role of autophagy and 686 
mitophagy in PD; several recently published screens have investigated modulators of 687 
these processes [205,206]. One study even identifying the mechanism of action of an 688 
autophagy modulator being complex I inhibition. This once again highlights the overlap 689 
between mitochondrial function and the autophagy/lysosomal pathways. 690 
In conclusion, mitochondrial abnormalities are a feature of both sporadic and familial 691 
forms of PD and AD. Several approaches have been taken to target these mitochondrial 692 
abnormalities therapeutically, some directly targeting mitochondria and some via an 693 
indirect mechanism. Several of these approaches are promising avenues to explore 694 
further in addition to novel compound screening approaches targeting mitochondrial 695 
abnormalities. 696 
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Figure 1. Example phenotypic screening pipeline. This figure outlines the various 1469 
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testing of robustness and assessing suitability of the screening assay. This stage can 1471 
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often be the most time consuming stage to set up. Stage 2 is the primary screen, 1472 
considerations at this stage include through put, size of library and number of times the 1473 
screen will be run. Stage 3 is the secondary screening phase which includes excluding 1474 
false positives, toxicity testing and validating a positive effect on the pathway via an 1475 
alternative methodology. Stage 4 is the tertiary screening, in depth characterisation of 1476 
the pathway in other model systems which is coupled with the often extensive and time 1477 
consuming target identification step. Step 5 then is the hit to lead optimisation and 1478 
structure activity relationship with medicinal chemistry input. This step could involve 1479 
designing a complete new screen dependent on the target identified in step 4. This 1480 
pathway is simply a representation of the steps which could be undertaken in 1481 
phenotypic screening and does not depict the only pathway to follow. 1482 
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